A natural compound derivative P-13 inhibits STAT3 signaling by covalently inhibiting Janus kinase 2

[1]  Huan Wang,et al.  A novel small molecular STAT3 inhibitor, 5Br-6b, induces apoptosis and inhibits migration in colorectal cancer cells , 2018, Anti-cancer drugs.

[2]  J. Marks,et al.  JAK2-binding long noncoding RNA promotes breast cancer brain metastasis , 2017, The Journal of clinical investigation.

[3]  H. Zoghbi,et al.  Jak2-mediated phosphorylation of Atoh1 is critical for medulloblastoma growth , 2017, eLife.

[4]  L. Morel,et al.  Role of STAT3 in Genesis and Progression of Human Malignant Gliomas , 2017, Molecular Neurobiology.

[5]  Jun Chen,et al.  Phosphorylation of STAT3 at Tyr705 regulates MMP-9 production in epithelial ovarian cancer , 2017, PloS one.

[6]  S. Stylli,et al.  STAT3 signaling mediates tumour resistance to EGFR targeted therapeutics , 2017, Molecular and Cellular Endocrinology.

[7]  H. Pan,et al.  Correlation between p-STAT3 overexpression and prognosis in lung cancer: A systematic review and meta-analysis , 2017, PloS one.

[8]  Giedrius Steponaitis,et al.  Signal transducer and activator of transcription 3 (STAT3) promoter methylation and expression in pituitary adenoma , 2017, BMC Medical Genetics.

[9]  S. Verstovsek,et al.  JAK2 inhibitors for myeloproliferative neoplasms: what is next? , 2017, Blood.

[10]  S. Ye,et al.  STAT3 activation in endothelial cells is important for tumor metastasis via increased cell adhesion molecule expression , 2017, Oncogene.

[11]  Yuka Kanno,et al.  Mechanisms and consequences of Jak–STAT signaling in the immune system , 2017, Nature Immunology.

[12]  D. Schwartz,et al.  JAK–STAT Signaling as a Target for Inflammatory and Autoimmune Diseases: Current and Future Prospects , 2017, Drugs.

[13]  D. Schwartz,et al.  Erratum to: JAK–STAT Signaling as a Target for Inflammatory and Autoimmune Diseases: Current and Future Prospects , 2017, Drugs.

[14]  M. Wainberg,et al.  JAK-STAT Signaling Pathways and Inhibitors Affect Reversion of Envelope-Mutated HIV-1 , 2017, Journal of Virology.

[15]  M. Hu,et al.  Activating JAK 2 mutants reveal cytokine receptor coupling differences that impact outcomes in myeloproliferative neoplasm , 2017 .

[16]  Juan Carlos Hernández Boluda,et al.  Inhibidores de JAK2 , 2016 .

[17]  Haluk Resat,et al.  Constitutive activation of STAT3 in breast cancer cells: A review , 2016, International journal of cancer.

[18]  J. Grandis,et al.  The STAT3 pathway as a therapeutic target in head and neck cancer: Barriers and innovations. , 2016, Oral oncology.

[19]  Yonghong Liu,et al.  Dicarabrol, a new dimeric sesquiterpene from Carpesium abrotanoides L. , 2015, Bioorganic & medicinal chemistry letters.

[20]  H. Yin,et al.  Covalent modification of DNA by α, β-unsaturated aldehydes derived from lipid peroxidation: Recent progress and challenges , 2015, Free radical research.

[21]  Massimo Gadina,et al.  The JAK-STAT pathway: impact on human disease and therapeutic intervention. , 2015, Annual review of medicine.

[22]  Yuka Kanno,et al.  Mechanisms of Jak/STAT Signaling in Immunity and Disease , 2015, The Journal of Immunology.

[23]  Songmun Kim,et al.  Carpesium abrotanoides extract inhibits inducible nitric oxide synthase expression induced by toll-like receptor agonists , 2014, Food Science and Biotechnology.

[24]  R. Mesa,et al.  Janus kinase inhibitors for the treatment of myeloproliferative neoplasms , 2014, Expert opinion on pharmacotherapy.

[25]  Mark E Flanagan,et al.  Discovery and development of Janus kinase (JAK) inhibitors for inflammatory diseases. , 2014, Journal of medicinal chemistry.

[26]  Matthew R. Pratt,et al.  An alkyne-aspirin chemical reporter for the detection of aspirin-dependent protein modification in living cells. , 2013, Journal of the American Chemical Society.

[27]  Martha L Slattery,et al.  JAK/STAT/SOCS‐signaling pathway and colon and rectal cancer , 2013, Molecular carcinogenesis.

[28]  R. Davis,et al.  The JAK inhibitor AZD1480 regulates proliferation and immunity in Hodgkin lymphoma , 2011, Blood cancer journal.

[29]  P. Leclerc,et al.  Mediators of the JAK/STAT Signaling Pathway in Human Spermatozoa1 , 2011, Biology of reproduction.

[30]  G. Bottegoni,et al.  Non-ATP competitive protein kinase inhibitors. , 2010, Current medicinal chemistry.

[31]  J. S. Rao,et al.  Stat3-siRNA induces Fas-mediated apoptosis in vitro and in vivo in breast cancer. , 2009, International journal of oncology.

[32]  J. O’Shea,et al.  Janus kinases in immune cell signaling , 2009, Immunological reviews.

[33]  Jiayuh Lin,et al.  STAT3 can be activated through paracrine signaling in breast epithelial cells , 2008, BMC Cancer.

[34]  M. Moasser,et al.  The epidermal growth factor receptor family: Biology driving targeted therapeutics , 2008, Cellular and Molecular Life Sciences.

[35]  O. Silvennoinen,et al.  The Janus kinases (Jaks) , 2004, Genome Biology.

[36]  D. Harrison,et al.  The JAK/STAT signaling pathway , 2004, Journal of Cell Science.

[37]  D. Aaronson,et al.  A Road Map for Those Who Don't Know JAK-STAT , 2002, Science.

[38]  Michael Karin,et al.  The IκB kinase (IKK) and NF-κB: key elements of proinflammatory signalling , 2000 .

[39]  J. Darnell,et al.  Stat3 as an Oncogene , 1999, Cell.

[40]  M. Karin,et al.  The I kappa B kinase (IKK) and NF-kappa B: key elements of proinflammatory signalling. , 2000, Seminars in immunology.